AR126584A1 - Inhibidores de pgdh de pirrolo[2,3-b]piridina y métodos para hacerlos y usarlos - Google Patents
Inhibidores de pgdh de pirrolo[2,3-b]piridina y métodos para hacerlos y usarlosInfo
- Publication number
- AR126584A1 AR126584A1 ARP220101992A ARP220101992A AR126584A1 AR 126584 A1 AR126584 A1 AR 126584A1 AR P220101992 A ARP220101992 A AR P220101992A AR P220101992 A ARP220101992 A AR P220101992A AR 126584 A1 AR126584 A1 AR 126584A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkyl
- nr8r9
- cycloalkyl
- Prior art date
Links
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 title 2
- 102100028207 6-phosphogluconate dehydrogenase, decarboxylating Human genes 0.000 title 1
- 101710151348 D-3-phosphoglycerate dehydrogenase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 229940122256 15-hydroxyprostaglandin dehydrogenase inhibitor Drugs 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento, se divulgan compuestos inhibidores de 15-hidroxiprostaglandina deshidrogenasa. Tales compuestos pueden administrarse a sujetos para los que la modulación de las cantidades de prostaglandina puede resultar beneficiosa. Reivindicación 1: Un compuesto de fórmula (1), o una sal o solvato farmacéuticamente aceptable de este; caracterizado porque, el anillo Q es arilo C₆ o heteroarilo de 5 a 10 miembros; W es -CR⁶R⁶ -, -O-, -S-, -NR⁵ -, -S(O)₂- o -C(O)-; R¹ y R² son cada uno independientemente H, halógeno, -CN, -OR¹⁰, -C(O)R¹⁰, -C(O)OR¹⁰, -NR⁸R⁹, -C(O)NR⁸R⁹, alquilo C₁-C₆ sustituido o no sustituido, o sustituido o cicloalquilo C₃-C₈ no sustituido; cada R³ se selecciona independientemente de H, halógeno, -CN, -NR⁸R⁹, -OR¹⁰, CN, -C(O)R¹⁰, -C(O)OR¹⁰, -C(O)NR⁸R⁹, -SOR¹¹, -SO₂R¹¹, -SO₂NR⁸R⁹, -NR¹²C(O)R¹⁰, -NR¹²C(O)OR¹⁰, -NR¹²C(O)NR⁸R⁹, -OC(O)NR⁸R⁹, - NR¹²SO₂R¹⁰, -NR¹²SO₂NR⁸R⁹, alquilo C₁-C₆ sustituido o no sustituido, haloalquilo C₁-C₆ sustituido o no sustituido, cicloalquilo C₃-C₈ sustituido o no sustituido, heterocicloalquilo C₃-C₈ sustituido o no sustituido, arilo C₆ sustituido o no sustituido, o heteroarilo de 5 a 10 miembros sustituido o no sustituido; R⁵ es H, alquilo C₁-C₆ o -C(O)R¹⁰; cada R⁶ es independientemente H, halógeno, CN, -NR⁸R⁹, -OR¹⁰, -C(O)R¹⁰, - C(O)OR¹⁰, -C(O)NR⁸R⁹, -SOR¹¹, -SO₂R¹¹, alquilo C₁-C₆ sustituido o no sustituido; o dos R⁶ pueden juntarse con los átomos a los que se adjuntan para formar un anillo de cicloalquilo C₃-C₆ o heterocicloalquilo C₃-C₈; R⁷ es H, halógeno, -CN, -NR¹⁰R¹⁰, -OR¹⁰, -C(O)R¹⁰, -C(O)OR¹⁰, o alquilo C₁-C₆ sustituido o no sustituido; cada R⁸ y R⁹ se seleccionan independientemente en cada aparición de H, alquilo C₁-C₆, alquenilo C₂-C₆, alquinilo C₂-C₆, heteroalquilo C₁-C₆, haloalquilo C₁-C₆ y cicloalquilo C₃-C₁₀; cada R¹⁰ se selecciona independientemente de H, alquilo C₁-C₆, alquenilo C₂-C₆, heteroalquilo C₁-C₆, haloalquilo C₁-C₆, cicloalquilo C₃-C₈, arilo C₆-C₁₀ y heteroarilo de 5 a 10 miembros; cada R¹¹ se selecciona independientemente de alquilo C₁-C₆, alquenilo C₂-C₆, heteroalquilo C₁-C₆, haloalquilo C₁-C₆, cicloalquilo C₃-C₈, arilo C₆-C₁₀ y heteroarilo de 5 a 10 miembros; cada R¹² se selecciona independientemente de H, alquilo C₁-C₆, alquenilo C₂-C₆, haloalquilo C₁-C₆ y cicloalquilo C₃-C₈; n y m son cada uno independientemente 0, 1, 2 o 3; q es 0, 1, 2 o 3; y p es 1, 2, 3 o 4. Reivindicación 65: Una composición farmacéutica caracterizada porque comprende un compuesto de una cualquiera de las reivindicaciones 1 a 64, o una sal o solvato farmacéuticamente aceptable de este, y un excipiente farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163226670P | 2021-07-28 | 2021-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126584A1 true AR126584A1 (es) | 2023-10-25 |
Family
ID=85088004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101992A AR126584A1 (es) | 2021-07-28 | 2022-07-27 | Inhibidores de pgdh de pirrolo[2,3-b]piridina y métodos para hacerlos y usarlos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240294519A1 (es) |
| EP (1) | EP4376841A4 (es) |
| JP (1) | JP2024529508A (es) |
| KR (1) | KR20240102934A (es) |
| CN (1) | CN118338902A (es) |
| AR (1) | AR126584A1 (es) |
| AU (1) | AU2022319753A1 (es) |
| CA (1) | CA3227277A1 (es) |
| IL (1) | IL310438A (es) |
| TW (1) | TW202310836A (es) |
| WO (1) | WO2023009642A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12249948B2 (en) | 2022-08-30 | 2025-03-11 | Schweitzer Engineering Laboratories, Inc. | Split-phase protection of generators |
| WO2024158931A1 (en) * | 2023-01-25 | 2024-08-02 | Epirium Bio Inc. | Pgdh inhibitors and methods of making and using |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201711234D0 (en) * | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
| IL294881A (en) * | 2020-01-23 | 2022-09-01 | Myoforte Therapeutics Inc | pgdh inhibitors and methods of preparation and use |
| EP4228650A4 (en) * | 2020-10-15 | 2024-12-18 | Myoforte Therapeutics Inc. | INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF |
-
2022
- 2022-07-27 CA CA3227277A patent/CA3227277A1/en active Pending
- 2022-07-27 JP JP2024505514A patent/JP2024529508A/ja active Pending
- 2022-07-27 KR KR1020247005938A patent/KR20240102934A/ko active Pending
- 2022-07-27 WO PCT/US2022/038548 patent/WO2023009642A1/en not_active Ceased
- 2022-07-27 AU AU2022319753A patent/AU2022319753A1/en active Pending
- 2022-07-27 AR ARP220101992A patent/AR126584A1/es unknown
- 2022-07-27 TW TW111128208A patent/TW202310836A/zh unknown
- 2022-07-27 EP EP22850260.5A patent/EP4376841A4/en active Pending
- 2022-07-27 CN CN202280065454.XA patent/CN118338902A/zh active Pending
- 2022-07-27 US US18/292,856 patent/US20240294519A1/en active Pending
- 2022-07-27 IL IL310438A patent/IL310438A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227277A1 (en) | 2023-02-02 |
| EP4376841A1 (en) | 2024-06-05 |
| AU2022319753A1 (en) | 2024-02-22 |
| KR20240102934A (ko) | 2024-07-03 |
| US20240294519A1 (en) | 2024-09-05 |
| JP2024529508A (ja) | 2024-08-06 |
| IL310438A (en) | 2024-03-01 |
| EP4376841A4 (en) | 2025-06-18 |
| CN118338902A (zh) | 2024-07-12 |
| TW202310836A (zh) | 2023-03-16 |
| WO2023009642A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR126584A1 (es) | Inhibidores de pgdh de pirrolo[2,3-b]piridina y métodos para hacerlos y usarlos | |
| AR121719A1 (es) | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| AR121669A1 (es) | Compuesto de piridazina sustituida | |
| AR119697A1 (es) | Azepino-indoles y otros heterociclos para tratar trastornos cerebrales | |
| AR090230A1 (es) | Derivados macrociclicos para el tratamiento de enfermedades | |
| AR122986A1 (es) | Derivados de piridazina como inhibidores de alk5 y/o alk4 | |
| AR087742A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina | |
| AR123848A1 (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
| AR126693A1 (es) | Compuestos de pirazolopiridinona | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR100713A1 (es) | Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor | |
| AR119910A1 (es) | DERIVADOS DE 4,4a,5,7,8,8a-HEXAHIDROPIRIDO[4,3-b][1,4]OXAZIN-3-ONA COMO INHIBIDORES DE MAGL | |
| AR115464A1 (es) | Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| AR121676A1 (es) | DERIVADOS DE BENZODIAZEPINAS COMO PAM DE GABAA g1 | |
| AR116400A1 (es) | Compuesto de imidazopiridinona | |
| AR117122A1 (es) | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| AR118641A1 (es) | Compuestos, composiciones y métodos | |
| AR123701A1 (es) | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR123700A1 (es) | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 |